China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $5 | $1 | $0 |
| % Growth | -16.4% | 668% | 18% | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | $3 | $3 | $0 | $0 |
| % Margin | 75% | 75.1% | 74.4% | 74.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $2 | $2 | $2 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $0 | $0 |
| Operating Income | $1 | $1 | $0 | $0 |
| % Margin | 22.3% | 21.6% | 18.1% | 16.6% |
| Other Income/Exp. Net | $0 | -$1 | $0 | $0 |
| Pre-Tax Income | $1 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | $0 | $0 | $0 |
| % Margin | 22.2% | 3% | 18.3% | 17.3% |
| EPS | 1.11 | 0.18 | 0.14 | 0.11 |
| % Growth | 516.7% | 28.6% | 27.3% | – |
| EPS Diluted | 1.11 | 0.18 | 0.14 | 0.11 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $1 | $0 | $0 |
| % Margin | 32.3% | 27.7% | 24.7% | 24.4% |